Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy
Jiannong Li,Inna Smalley,Zhihua Chen,Jheng-Yu Wu,Manali S Phadke,Jamie K Teer,Thanh Nguyen,Florian A Karreth,John M Koomen,Amod A Sarnaik,Jonathan S Zager,Nikhil I Khushalani,Ahmad A Tarhini,Vernon K Sondak,Paulo C Rodriguez,Jane L Messina,Y Ann Chen,Keiran S M Smalley
DOI: https://doi.org/10.1158/1078-0432.CCR-21-3145
IF: 13.801
2022-01-01
Clinical Cancer Research
Abstract:Purpose: Acral melanoma is a rare subtype of melanoma that arises on the non-hair-bearing skin of the palms, soles, and nail beds. In this study, we used single-cell RNA sequencing (scRNAseq) to map the transcriptional landscape of acral melanoma and identify novel immunotherapeutic targets. Experimental Design: We performed scRNA-seq on nine clinical specimens (five primary, four metastases) of acral melanoma. Detailed cell type curation was performed, the immune landscapes were mapped, and key results were validated by analysis of The Cancer Genome Atlas (TCGA) and single-cell datasets. Cell-cell interactions were inferred and compared with those in nonacral cutaneous melanoma. Results: Multiple phenotypic subsets of T cells, natural killer (NK) cells, B cells, macrophages, and dendritic cells with varying levels of activation/exhaustion were identified. A comparison between primary and metastatic acral melanoma identified gene signatures associated with changes in immune responses and metabolism. Acral melanoma was characterized by a lower overall immune infiltrate, fewer effector CD8 T cells and NK cells, and a near-complete absence of gd T cells compared with nonacral cutaneous melanomas. Immune cells associated with acral melanoma exhibited expression of multiple check-points including PD-1, LAG-3, CTLA-4, V-domain immunoglo-bin suppressor of T cell activation (VISTA), TIGIT, and the Adenosine A2A receptor (ADORA2). VISTA was expressed in 58.3% of myeloid cells and TIGIT was expressed in 22.3% of T/NK cells. Conclusions: Acral melanoma has a suppressed immune envi-ronment compared with that of cutaneous melanoma from non-acral skin. Expression of multiple, therapeutically tractable immune checkpoints were observed, offering new options for clinical translation.